Pharmacokinetic and pharmacodynamic properties of canakinumab in patients with gouty arthritis.

@article{Chakraborty2013PharmacokineticAP,
  title={Pharmacokinetic and pharmacodynamic properties of canakinumab in patients with gouty arthritis.},
  author={Abhijit Chakraborty and Linh M Van and Andrej Skerjanec and David Floch and Ulf R Klein and Gerhard Krammer and Gangadhar Sunkara and Dan Howard},
  journal={Journal of clinical pharmacology},
  year={2013},
  volume={53 12},
  pages={1240-51}
}
Pharmacokinetics and pharmacodynamics of the anti-interleukin (IL)-1β monoclonal antibody, canakinumab, in gouty arthritis patients from three studies are reported. Canakinumab has low serum clearance (0.214 L/day), low steady-state volume of distribution (7.44 L), a 25.8-day half-life, and approximately 60% subcutaneous absolute bioavailability in a typical 93-kg patient. Creatinine clearance had a small positive impact on serum canakinumab clearance that is not likely to be clinically… CONTINUE READING